Skip to main content
Premium Trial:

Request an Annual Quote

Affymetrix Inks Two Deals for GeneChip Technology

NEW YORK, Oct. 20 (GenomeWeb News) - Affymetrix said today that it has signed two separate deals granting partners access to its GeneChip microarray technology.

 

Under the first, diagnostics firm Biomerieux will have the non-exclusive right to use the GeneChip technology in the development of tests for virulence factors, bacterial strain typing, and sepsis diagnosis.  This arrangement, which expands an ongoing collaboration between the companies, also gives Biomerieux rights to use the technology to develop assays for hepatitis C, as well as respiratory and central nervous system infectious panels.

 

Affymetrix will receive upfront and milestone payments in exchange for the GeneChip technology, as well as royalties on product sales.

 

Under the second deal, Paradigm Genetics will begin offering its customers microarray processing services using the GeneChip technology.  Paradigm will also have the right to use certain Affymetrix technologies for its internal research efforts.

 

Financial details of the Paradigm arrangement were not disclosed.

The Scan

Researchers Compare WGS, Exome Sequencing-Based Mendelian Disease Diagnosis

Investigators find a diagnostic edge for whole-genome sequencing, while highlighting the cost advantages and improving diagnostic rate of exome sequencing in EJHG.

Researchers Retrace Key Mutations in Reassorted H1N1 Swine Flu Virus With Avian-Like Features

Mutations in the acidic polymerase-coding gene boost the pathogenicity and transmissibility of Eurasian avian-like H1N1 swine influenza viruses, a PNAS paper finds.

Genome Sequences Reveal Evolutionary History of South America's Canids

An analysis in PNAS of South American canid species' genomes offers a look at their evolutionary history, as well as their relationships and adaptations.

Lung Cancer Response to Checkpoint Inhibitors Reflected in Circulating Tumor DNA

In non-small cell lung cancer patients, researchers find in JCO Precision Oncology that survival benefits after immune checkpoint blockade coincide with a dip in ctDNA levels.